panel of independent FDA advisers is meeting today to consider the merits of Spark Therapeutics’ (ONCE) Luxturna, a one-time gene therapy meant to treat a rare, inherited form of childhood blindness.

If the panel votes yes and the FDA follows its recommendation, Luxturna would become the first therapy meant to replace or repair a defective gene approved in the U.S. Spark hasn’t disclosed pricing, but analysts estimate Luxturna could cost $1 million or more per patient, a price that might force payers and insurers to rethink their coverage and reimbursement models.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Buenas tardes, quisiera que por favor me ayudaran tengo una sobrina de 38 anos , es sordomuda y tiene sindrome de Usher, retinitis pigmentosa, ha perdido la vision de los lados , este tratamiento pudiera ayudarle a ella, por favor me indican el costo es una persona de muy bajos recursos, se deprime mucho por esta condicion y no se como ayudarla. Gracias por ayudarnos Dios les de mucha sabiduria para que continuen en tan excelente labor.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.